EFG International AG Makes New $5.53 Million Investment in Repligen Corporation $RGEN

EFG International AG purchased a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the second quarter, HoldingsChannel.com reports. The institutional investor purchased 40,543 shares of the biotechnology company’s stock, valued at approximately $5,529,000.

Other large investors have also made changes to their positions in the company. AQR Capital Management LLC purchased a new stake in Repligen during the first quarter worth about $262,000. Jones Financial Companies Lllp lifted its position in shares of Repligen by 3,850.6% during the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after acquiring an additional 6,238 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Repligen by 16.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after acquiring an additional 20,375 shares during the period. Bank of Nova Scotia boosted its stake in shares of Repligen by 88.0% during the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock worth $3,951,000 after acquiring an additional 14,860 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Repligen by 29.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after acquiring an additional 7,148 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

RGEN has been the topic of a number of research reports. Wells Fargo & Company upped their price target on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Zacks Research upgraded Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Evercore reissued an “outperform” rating and issued a $160.00 target price on shares of Repligen in a report on Monday, July 6th. Citigroup upgraded Repligen to a “buy” rating in a research report on Tuesday, July 7th. Finally, Wolfe Research assumed coverage on Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $166.43.

Repligen Trading Up 0.0%

Shares of RGEN opened at $181.69 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The firm has a 50 day simple moving average of $149.17 and a 200-day simple moving average of $132.22. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $188.73. The stock has a market cap of $10.25 billion, a price-to-earnings ratio of 248.89, a price-to-earnings-growth ratio of 3.31 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts forecast that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.